Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Duvelisib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | chronic lymphocytic leukemia | sensitive | Duvelisib | Preclinical - Pdx | Actionable | In a preclinical study, Copiktra (duvelisib) treatment resulted in a reduction of leukemia cells in the spleen of a patient-derived xenograft (PDX) model of chronic lymphocytic leukemia harboring BTK C481S (PMID: 37071496). | 37071496 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37071496) | Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model. | Full reference... |